Literature DB >> 10389700

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

P Gionchetti, F Rizzello, A Ferrieri, A Venturi, C Brignola, M Ferretti, S Peruzzo, M Miglioli, M Campieri.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389700     DOI: 10.1023/a:1026648812439

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  3 in total

1.  The efficacy of tobramycin in the treatment of ulcerative colitis.

Authors:  D A Burke; A T Axon; S A Clayden; M F Dixon; D Johnston; R W Lacey
Journal:  Aliment Pharmacol Ther       Date:  1990-04       Impact factor: 8.171

2.  Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.

Authors:  G J Mantzaris; A Hatzis; P Kontogiannis; G Triadaphyllou
Journal:  Am J Gastroenterol       Date:  1994-01       Impact factor: 10.864

3.  Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

Authors:  J J Descombe; D Dubourg; M Picard; E Palazzini
Journal:  Int J Clin Pharmacol Res       Date:  1994
  3 in total
  34 in total

Review 1.  Bacteria as the cause of ulcerative colitis.

Authors:  M Campieri; P Gionchetti
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

Review 2.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

4.  A meta-analysis of antibiotic therapy for active ulcerative colitis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

Review 5.  Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Authors:  Kaitlin G Whaley; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

Review 6.  AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Authors:  Jean-Frederic Colombel; Andrea Shin; Peter R Gibson
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

7.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

8.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 9.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

10.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.